Lifevantage (LFVN) Stock Price, News & Analysis

Company Overview

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market. The company’s research and development efforts focus on leveraging cellular biology insights to create products that support antioxidant activity and overall well-being. Its sales force operates on a multi-level marketing framework, earning commissions through personal and team retail sales.

LifeVantage maintains a global presence, with active markets in North America, Europe, Asia-Pacific and South Africa. Through this international footprint, the company serves health-conscious consumers across more than 30 markets. Distributors utilize online platforms and in-person presentations to educate customers about the science behind each product and to build a recurring revenue base.

Governed by a board of directors and a senior management team, LifeVantage places emphasis on product innovation, regulatory compliance and distributor training. The company continues to explore partnerships and clinical collaborations aimed at validating its formulations and expanding its reach within the competitive health and wellness industry.

Key Stats

• Today's Range: $10.52 to $10.85
• 50-Day Range: $10.68 to $14.51
• 52-Week Range: $9.83 to $27.38
• Volume: 86,421 shs
• Average Volume: 165,173 shs
• Market Capitalization: $135.91 million
• P/E Ratio: 14.47
• Dividend Yield: 1.68%
• Price Target: $30.50
• Consensus Rating: Buy

Lifevantage Stock Analysis - MarketRank™

Lifevantage scored higher than 80% of companies evaluated by MarketBeat, and ranked 217th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lifevantage has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Lifevantage has a consensus price target of $30.50, representing about 184.8% upside from its current price of $10.71.

Amount of Analyst Coverage

Lifevantage has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lifevantage is 14.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lifevantage is 14.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.86.

Price to Book Value per Share Ratio

Lifevantage has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.97% of the float of Lifevantage has been sold short.

Short Interest Ratio / Days to Cover

Lifevantage has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Lifevantage has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Lifevantage pays a meaningful dividend of 1.69%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Lifevantage has only been increasing its dividend for 3 years.

Dividend Coverage

The dividend payout ratio of Lifevantage is 24.32%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: 2.7 / 5
• Environmental Score: -1.50

Percentage of Shares Shorted

24.97% of the float of Lifevantage has been sold short.

Short Interest Ratio / Days to Cover

Lifevantage has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Lifevantage has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.57

News Sentiment

Lifevantage has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Lifevantage this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for LFVN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Lifevantage to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lifevantage insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $86,229.00 in company stock.

Percentage Held by Insiders

20.65% of the stock of Lifevantage is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 35.32% of the stock of Lifevantage is held by institutions.

LFVN Stock Analysis - Frequently Asked Questions

How have LFVN shares performed this year?

Lifevantage's stock was trading at $17.53 at the beginning of 2025. Since then, LFVN stock has decreased by 38.9% and is now trading at $10.71.

How were Lifevantage's earnings last quarter?

Lifevantage Corporation (NASDAQ:LFVN) issued its quarterly earnings data on Thursday, September, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.17. The company had revenue of $55.11 million for the quarter, compared to the consensus estimate of $57.93 million. Lifevantage had a net margin of 4.29% and a trailing twelve-month return on equity of 33.75%.
Read the conference call transcript.

Who are Lifevantage's major shareholders?

Top institutional shareholders of Lifevantage include Capital Management Corp VA (10.06%), Wasatch Advisors LP (3.55%), Geode Capital Management LLC (1.95%) and Acadian Asset Management LLC (1.78%). Insiders that own company stock include Judd Dayton, Carl Aure, Darwin Lewis, Raymond B Greer, Garry Paul Mauro and Michael A Beindorff.
View institutional ownership trends.

How do I buy shares of Lifevantage?

Shares of LFVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lifevantage own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lifevantage investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 9/04/2025
• Record date for 9/16 Dividend: 9/08/2025
• Ex-Dividend for 9/16 Dividend: 9/08/2025
• Today: 9/16/2025
• Dividend Payable: 9/16/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LFVN
• CIK: 849146
• Web: www.lifevantage.com
• Phone: (801) 432-9000
• Fax: 801-880-0699
• Employees: 260
• Year Founded: 1988

Price Target and Rating

• Average Price Target for Lifevantage: $30.50
• High Price Target: $35.00
• Low Price Target: $26.00
• Potential Upside/Downside: +184.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.74
• Trailing P/E Ratio: 14.48
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $9.81 million
• Net Margins: 4.29%
• Pretax Margin: 5.36%
• Return on Equity: 33.75%
• Return on Assets: 15.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.87
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $228.53 million
• Price / Sales: 0.60
• Cash Flow: $1.06 per share
• Price / Cash Flow: 10.12
• Book Value: $2.75 per share
• Price / Book: 3.90

Miscellaneous

• Outstanding Shares: 12,690,000
• Free Float: 10,070,000
• Market Cap: $136.04 million
• Optionable: Optionable
• Beta: 0.39